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https://doi.org/10.1016/j.stemcr.2018.01.031SUMMARYDeveloping effective therapeutics for complex diseases such as late-onset, sporadic Alzheimer’s disease (SAD) is difficult due to genetic
and environmental heterogeneity in the human population and the limitations of existing animal models. Here, we used hiPSC-derived
neurons to test a compound that stabilizes the retromer, a highly conservedmultiprotein assembly that plays a pivotal role in trafficking
molecules through the endosomal network. Using this human-specific system, we have confirmed previous data generated in murine
models and show that retromer stabilization has a potentially beneficial effect on amyloid beta generation fromhuman stem cell-derived
neurons.We further demonstrate thatmanipulation of retromer complex levels within neurons affects pathogenic TAUphosphorylation
in an amyloid-independentmanner. Taken together, our work demonstrates that retromer stabilization is a promising candidate for ther-
apeutic development in AD and highlights the advantages of testing novel compounds in a human-specific, neuronal system.INTRODUCTION
Alzheimer’s disease (AD) is a devastating disorder of the
brain and a rapidly growing public health problem. Pa-
tients with raremutations in the amyloid precursor protein
(APP) and presenilin 1 and 2 genes (PSEN 1 and PSEN 2)
make up about 5% of familial AD cases (FAD) while the
vast majority of AD is late-onset, sporadic AD (SAD) (Avra-
mopoulos, 2009). SAD is a complex and heterogeneous dis-
order with a clear heritable component that defines genetic
risk (Gatz et al., 2006) but with unknown contributions
from the environment. The lack of effective therapies for
AD is, in large part, due to our lack of understanding of
the cellular and molecular mechanisms that lead to the
neuropathological outcomes of the disease. Reasons for
this are several-fold. In particular, AD takes decades toman-
ifest clinically, and irreversible cellular damage likely occurs
before the overt clinical symptoms are detected. In addi-
tion, the human brain is an inaccessible organ, making it
difficult to sample tissue from living patients. Human
induced pluripotent stem cells (hiPSCs) have facilitated
the development of human neuronal models for AD, as
they can be differentiated into disease-appropriate cell
types and maintain the unique patient genetic back-
ground. To date, AD has been successfully modeled using
patient and isogenic cell lines, and disease-relevant pheno-
types have been well-documented from stem cell-derived1046 Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 j ª 2018 The
This is an open access article under the CC BY-NC-ND license (http://creativneurons for both FAD and SAD (Israel et al., 2012; Kondo
et al., 2013; Muratore et al., 2014; Raja et al., 2016; Wood-
ruff et al., 2013; Yagi et al., 2011; Young et al., 2015).
We and others have demonstrated a role for endocytic
genes in AD risk (Karch and Goate, 2015; Rogaeva et al.,
2007; Young et al., 2015), and elegant microscopic anal-
ysis has documented enlarged endosomes and suggested
endocytic dysfunction as an early phenotype in AD
pathogenesis (Cataldo et al., 2000, 2008; Nixon et al.,
2005). This work has been recapitulated in stem cell-
derived neurons (Israel et al., 2012; Raja et al., 2016);
however, to date, no AD therapy targets the endosomal
network, likely due to the complexity of its structure
and regulation.
Retromer is a multiprotein assembly with a primary role
in the sorting and trafficking of plasmamembrane proteins
from the endosomes, to the trans-Golgi network, or directly
back to the cell surface (Hu et al., 2015). APP is trafficked
through the endocytic network via retromer through its
interaction with SORLA, a member of the vacuolar pro-
tein-sorting VPS10 family of sorting receptors and a well-
defined AD risk gene (Fjorback et al., 2012; Reitz et al.,
2011, 2013; Rogaeva et al., 2007). The retromer assembly
has two major components, including the cargo-recogni-
tion complex (CRC), a trimeric core composed of VPS35,
VPS29, and VPS26 (Li et al., 2016). The second component
of retromer comprises the membrane targeting specificAuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
nexins, chiefly SNX1, SNX3, SNX5, SNX6, and SNX27
(Burd and Cullen, 2014). Retromer deficiency, primarily
loss of VPS35 and VPS26, has been described in SAD pa-
tients and increases Ab peptides in cell culture and cogni-
tive decline in the mouse brain (Bhalla et al., 2012; Mu-
hammad et al., 2008; Small et al., 2005; Wen et al., 2011).
Recently, novel pharmacological chaperones were devel-
oped that stabilize the trimeric core complex of VPS35,
VPS29, and VPS26. These molecules, R33 and R55, reduced
Ab in mouse hippocampal neurons in a retromer-depen-
dent manner (Mecozzi et al., 2014). Similarly, the retromer
stabilization molecule R55 reduced Ab in in a murine
neuronal cell line harboring the APP Swedish mutation
(Chu and Pratico, 2017). These studies support the idea
that increasing the levels and/or functions of endocytic
trafficking components may be viable options for thera-
peutic development in AD. However, to move forward in
investigation of therapeutic strategies for humans, it is crit-
ical to test candidates in a human-specific system. In addi-
tion, while Ab is a critical pathogenic readout for AD, how
retromer stabilization affects other components of the dis-
ease process, such as TAU hyperphosphorylation, and if
these two events are interdependent, is unknown. To
address these questions, we used hiPSC-derived neurons
from SAD and FADpatients and from genome-edited hiPSC
lines. This allowed us to modulate the amounts of Ab gen-
eration and APP expression in neurons and test how retro-
mer stabilization by the small molecule chaperone R33 af-
fects endogenous levels of Ab and phospho-TAU (pTAU) in
a human-specific system.RESULTS
Retromer Pharmacological Chaperones Reduce APP
Processing and Ab Peptides in hiPSC-Derived Neurons
from Non-demented Controls, SAD Patients, and FAD
Mutant Cells
The pharmacological chaperone R55 was previously
shown to stabilize the retromer core complex, reduce
Ab peptides, and decrease APP in endosomes in mouse
primary hippocampal neurons, suggesting that retromer
stabilization is beneficial in terms of AD pathogenesis
(Mecozzi et al., 2014). We extended these studies to
test the effect of retromer stabilization in human neu-
rons using an hiPSC approach. We tested both R55 and
its analog R33 in FACS-purified neurons derived from
non-demented control (NDC) hiPSCs. Our differentia-
tion protocol has consistently been shown to recapitu-
late key cellular AD phenotypes in a purified system, al-
lowing us to accurately quantitate analytes coming from
a particular cell type (i.e., human neurons) (Israel et al.,
2012; Young et al., 2015). We found that, in contrast tomouse neurons, R33 had a greater effect on Ab peptide
reduction than R55 in human neurons differentiated
from hiPSCs (Figure S1).
We then tested a cohort of cell lines derived from partic-
ipants in the University of California, San Diego (UCSD)
Alzheimer’s Disease Research Center (ADRC), which
included six NDCs and seven SAD patients (n = 13 patient
cell lines) (Figure 1A). We found that in cell lines derived
from either NDC or SAD subjects, R33 treatment for 72 hr
significantly reduced both Ab 1–40 and 1–42 peptide spe-
cies (Figures 1B–1E). Because this reduction occurred
equally for both Ab species, we did not observe significant
changes in the Ab 42:40 ratio (Figures 1F and 1G). This is
similar to what was previously observed in mouse hippo-
campal neurons, where retromer stabilization decreased
Ab 40 and 42 peptides equally (Mecozzi et al., 2014). We
observed variability among neuronal cultures in the
amount of increase in VPS35 stability, which could be
due to inherent variability between hiPSC lines, individual
patient genomes, or the limited amount of material ob-
tained from our purified neuron protocol (Figure S2A).
However, in representative experiments, we documented
detectable increases in VPS35 stability from purified
neuronal cultures (Figure S2B).
We next asked if retromer stabilization by R33 had an
effect in genetic backgrounds of penetrant mutations
leading to early-onset, FAD, either by increasing the
levels of APP (APP duplication, APPDp) or by enhancing
beta cleavage of APP (APP Swedish, APPSwe). In either pa-
tient neurons from FAD APPDp (Israel et al., 2012) or in
isogenic neurons in which the Swedish mutation was
introduced via CRISPR/Cas9 genome editing (Figure S2D)
(Woodruff et al., 2016), we observed a similar fold-
decrease in Ab peptides from APPDp patients and the
APPSwe isogenic neurons as with the NDC and SAD pa-
tient neurons (Figures 2A and 2B), suggesting that this
small molecule chaperone is a potent reducer of Ab,
despite patient or cell line genetic background. Indeed,
we observed a significant decrease in all forms of APP
processing (Figure 2C) and observed a reduction in APP
b-CTF in purified neurons treated with R33 (Figure 2D).
Interestingly, we did not observe a significant increase
in FL APP (Figure S2C), although this may be due to
the variability of APP expression across all our different
patient genetic backgrounds and the dynamic process
between APP cleavage and recycling, where changes in
APP cleavage may affect the overall expression of APP.
Future experiments are needed to determine how retro-
mer stabilization affects these processes. Taken together,
these data corroborate previous work in the mouse and
suggest that retromer stabilization keeps APP out of
intracellular compartments that generate b-cleavage of
APP and, subsequently, Ab.Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 1047
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Figure 1. Retromer Stabilizing Chaperone R33 Lowers Ab Peptides in hiPSC-Derived Neurons
(A) Schematic diagram of experimental design. hiPSCs were generated from fibroblast biopsies of six NDCs and seven probable SAD patients
from the UCSD ADRC. These lines have been previously published and characterized in Israel et al. (2012) and Young et al. (2015). FACS
purified neural stem cells and purified neurons were generated following previously published methods (Israel et al., 2012; Yuan et al.,
2011).
(B and C) Ab1-40 (B) and Ab1-42 (C) peptides in purified neurons derived from NDC individuals treated with vehicle (dots) or R33 (squares)
for 72 hr.
(D and E) Ab1-40 (D) and Ab1-42 (E) peptides in purified neurons derived from SAD patients treated with vehicle (dots) or R33 (squares)
for 72 hr.
(F and G) Ab 42:40 ratios in purified neurons derived from NDC (F) or SAD (G) patients treated with vehicle (dots) or R33 (squares) for 72 hr.
n = 6 NDC individuals (represented by dots/squares); two to four independent experiments/individual/treatment. n = 7 SAD individuals
(represented by dots/squares); two to four independent experiments/treatment.
Non-normally distributed data (A–E) were analyzed by Wilcoxon test. *p < 0.05. Normally distributed data (F and G) were analyzed by two-
tailed t test. NS, nonsignificant. All error bars represent SD. See also Figures S1 and S2.
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Figure 2. Retromer Stabilization Reduces
Ab Peptides in FAD Mutant Genetic Back-
grounds and Reduces Overall APP Process-
ing in Human Neurons
(A) R33 treatment significantly reduces Ab
peptides in hiPSC-derived neurons gener-
ated from a patient with an APP duplication
mutation (APPDp). n = 1 FAD individual,
three independent experiments/treatment.
(B) R33 treatment significantly reduces
Ab peptides in CRISPR/Cas9 gene-edited
isogenic neurons where the APP Swedish
(APPSwe) mutation was introduced into
wild-type (WT) cells by homologous recom-
bination n = 1–2 isogenic clones/genotype,
three independent experiments/treatment.
(C and D) R33 treatment reduces all APP
processing in human neurons, including Ab
sAPPa, sAPPb (C), and APP b CTF (D). n = 3
independent experiments/treatment.
For each comparison, a two-tailed t test
was performed. *p < 0.05, **p < 0.01,
***p < 0.001. Error bars represent SD. See
also Figure S2.Retromer Pharmacological Chaperones Reduce the
Phospho-TAU/Total TAU Ratio in hiPSC-Derived
Neurons by Decreasing the Level of Phosphorylated
TAU on Thr231
In addition to amyloid plaques, another neuropathological
hallmark of AD is the presence of neurofibrillary tangles
comprising hyperphosphorylated TAU protein. The
connection between Ab and TAU is complex, with the
dominant theory that Ab pathology precedes and drives
TAU pathology (Hardy and Higgins, 1992), while other ev-
idence suggests that these pathways can occur indepen-
dently (Small and Duff, 2008). Neurons purified from
hiPSCs have detectable levels of phosphorylated TAU on
Thr231 and this correlates with increases in Ab from APPDp
patients (Israel et al., 2012).We tested the effect of retromer
stabilization by R33 on the pTAU/total TAU (tTAU) ratio on
our cohort of patient neurons and found that R33 treat-
ment significantly decreased the pTAU/tTAU ratio in all
cell lines, whether they were derived from NDC or SAD in-
dividuals (Figures 3A and 3B). Interestingly, this decrease in
the ratio was due to an effect on pTAU (Figure 3C), while
the levels of tTAU in the cultures remained unchanged (Fig-ure 3D). R33 treatment had a similar effect on neurons
derived from an APPDp patient, with a reduction of pTAU
(Figure 3E), but not tTAU (Figure 3F), leading to a lowered
pTAU/tTAU ratio in these neurons (Figure 3G).
We probed a second pTAU epitope, paired helical frag-
ment (PHF) TAU, and observed that in the presence of com-
pound E, a gamma-secretase inhibitor, levels of PHF TAU
increased, but when neurons were concomitantly treated
with both compound E and R33, the PHF signal decreased
(Figure S3A).We tested whether R33 affected the activation
of the TAU kinase GSK3b (Figure S3B); however, we did not
observe a significant effect of R33 treatment on the activity
of GSK3b, suggesting that the decrease in pTAU by R33 is
mediated through a different mechanism.
Finally, we tested whether other molecules hypothesized
to be neurotrophic or protective against AD phenotypes
had a similar effect to R33 on the pTAU/tTAU ratio. We
have previously shown that the neurotrophin brain-
derived neurotrophic factor (BDNF) reduced Ab peptides
in stem cell-derived neurons and that this reduction
was correlated with protective variants in the SORL1
gene, whose protein product, SORLA, is a receptor of theStem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 1049
Ve
h
 R
33
0
5
10
15
20
pTau  
pT
au
: U
ni
ts
 p
er
 w
el
l Veh
 R33
***
 Ve
h
 R
33
0.00
0.05
0.10
0.15
0.20
pTau/tTau: NDC
pT
au
/tT
au
: R
at
io
 Veh
 R33
*
Veh R33
0.0
0.5
1.0
1.5
2.0
2.5
APP duplication neurons: pTau
pT
au
:u
ni
ts
 p
er
 w
el
l
Veh
R33
**
E
Ve
h
R3
3
0
20
40
60
80
APP duplication neurons: tTau
tT
au
: n
g/
m
l
Veh
R33
NS
F
G
Ve
h
R3
3
0.00
0.01
0.02
0.03
0.04
0.05
APP duplication neurons: 
pTau/tTau Ratio
pT
au
/tT
au
: R
at
io
Veh
R33
**
A B
DC
Ve
h
R3
3
0.00
0.05
0.10
0.15
pTau/tTau: SAD
pT
au
/tT
au
: R
at
io
Veh
R33
*
Ve
h
R3
3
0
50
100
150
200
250
tTau
tT
au
: n
g/
m
l
Veh
R33
NS
Figure 3. Retromer Stabilization Reduces
the pTAU/tTAU Ratio in hiPSC-Derived
Neurons
(A) pTAU/tTAU ratio in purified neurons
derived from NDC individuals treated with
vehicle (dots) or R33 (squares) for 72 hr.
n = 6 NDC individuals (represented by dots/
squares); two to four independent experi-
ments/individual/treatment.
(B) pTAU/tTAU ratio in purified neurons
derived from NDC (SAD) individuals treated
with vehicle (dots) or R33 (squares) for
72 hr. n = 7 SAD individuals (represented by
dots/squares); two to four independent
experiments/treatment.
(C) R33 reduces the TAU ratio by lowering
phosphorylated TAU on Thr 231 in all sam-
ples (NDC and SAD neurons). n = 13 in-
dividuals (SAD + NDC) represented by dots/
squares; two to four independent experi-
ments/treatment.
(D) Levels of tTAU in all samples (NDC and
SAD neurons) are unaffected by R33 treat-
ment. n = 13 individuals (SAD + NDC) rep-
resented by dots/squares; two to four in-
dependent experiments/treatment.
(E) R33 reduces pTAU (Thr 231) in hiPSC
neurons derived from an APP duplication
patient.
(F) R33 does not affect tTAU levels in APP
duplication neurons.
(G) R33 decreases the pTAU/tTAU ratio in
APP duplication neurons.
Non-normally distributed data (A–D) were
analyzed by Wilcoxon test. *p < 0.05, ***p <
0.001. NS, nonsignificant. Error bars repre-
sent SD. (E–G) For APP duplication: n = 1
FAD individual, three independent experi-
ments/treatment. For each comparison,
a two-tailed t test was performed. **p <
0.01. NS, nonsignificant. Error bars repre-
sent SD. See also Figure S3.retromer complex (Young et al., 2015). BDNF has been
shown to reduce TAU phosphorylation, although at a
different epitope than is analyzed in this study, in retinoic
acid-differentiated SH-SY5Y cells (Chen et al., 2014). We
treated hiPSC-derived neurons from three cell lines
harboring SORL1 protective variants with BDNF and
measured the pTAU/tTAU ratio. Under these conditions,
however, we did not observe a significant change in the
TAU ratio (Figure S3C). Taken together, these data suggest
that the decrease in the pTAU/tTAU ratio by R33 has a
more specific effect on the stabilization of the trimeric
core cargo-recognition complex than on the various retro-
mer receptor or interacting proteins.1050 Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018Genetic Knockdown of VPS35 Increases Ab and
Phospho-TAU in Stem Cell-Derived Neurons
We next tested whether destabilization of the retromer
complex by knockdown of VPS35 had the opposite effect
of R33 treatment in hiPSC-derived neurons. Using lenti-
viral transduction, we expressed two independent short
hairpin RNAs (shRNAs) against VPS35 mRNA (determined
from a pool of four shRNAs, Figure S4A) in purified neurons
and documented significant increases in Ab peptides
similar to what has been previously reported in mice (Fig-
ures 4A and 4B) (Bhalla et al., 2012). We next measured
phosphorylated TAU protein (Thr 231) from purified neu-
rons transduced with two VPS35 shRNA and observed a
AC
D
E
B Figure 4. Knockdown of Retromer Assem-
bly Subunit VPS35 by shRNA Increases Ab
and pTAU/tTAU Ratio in hiPSC-Derived
Neurons
(A and B) Ab peptides (A, Ab1-40; B, Ab1-42)
measured from the cell culture media
of hiPSC-derived neurons are increased
when VPS35 levels are reduced by VPS35
shRNA (two shRNA, VPS35-c and VPS35-d)
compared with a scrambled shRNA (SCR
shRNA).
(C) pTAU levels increase in hiPSC-derived
neurons when VPS35 levels are reduced
by VPS35 shRNA (two shRNA, c and d)
compared with scrambled shRNA (SCR shRNA).
(D) VPS35 shRNA-c reduces VPS35 protein
by 50%.
(E) VPS 35 shRNA-c reduces VPS35 mRNA by
50%. n = 4 independent experiments per
treatment/condition.
(A–C) For each comparison, a one-way
ANOVA with a Tukey multiple comparisons
posttest was performed. (D and E) For each
comparison, a two-tailed t test was per-
formed. *p < 0.05, **p < 0.01, ***p<0.001.
Error bars represent SD. See also Figure S4.small but significant increase in pTAU at Thr 231 (Fig-
ure 4C). The magnitude of the increase in pTAU after
VPS35 knockdown is similar to that of the decrease in
pTAU we observe after R33 treatment. Because shRNA
VPS35-c gave the strongest effect, we confirmed the knock-
down of VPS35 protein and VPS35 mRNA using that
shRNA in multiple experiments (Figures 4D and 4E). We
consistently observed an approximately 50% knockdown
of VPS35 protein in our neuronal cultures (Figure 4D).
Although we are only able to reduce the levels of VPS35
protein by half, it should be noted that germline deletion
of VPS35 is results in embryonic lethality in mice and hap-
loinsufficiency of VPS35 is sufficient to increase AD neuro-
pathology in a transgenic mouse model (Wen et al., 2011).
These data suggest that even modest changes in retromer
subunit levels may have a large impact on cellular pheno-types. In terms of AD, we note that duplication of APP re-
sulting in one extra copy of the gene and 50% more APP
expression is sufficient to cause severe and early-onset AD
(Rovelet-Lecrux et al., 2006). Thus, for factors that may in-
crease or decrease risk but not the deterministic probability
of AD, changes on the order of 20% are likely relevant in
human disease.
Phospho-TAU Reduction Correlates with, but Is Not
Dependent on, Ab Peptide Levels
Because the magnitude of decrease in pTAU after R33
treatment was similar to the decreases observed in APP
processing, we performed a linear regression analysis on
absolute levels of pTAU and absolute levels of Ab in the
cultures across all 13 patient cell lines and found a positive
correlation between the reduction of Ab and the reductionStem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 1051
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Figure 5. The Decrease of Phosphory-
lated TAU Mediated by Retromer Stabili-
zation Is Correlative with, but Not Depen-
dent on, Decreases in Ab and sAPPb
(A) Absolute levels of Ab peptides from
13 patient cell lines were graphed against
absolute values of pTAU from hiPSC-derived
neurons and show a positive correlation be-
tween decreases in Ab and decreases in pTAU.
(B) Absolute levels of sAPPb peptides from
13 patient cell lines were graphed against
absolute values of pTAU from hiPSC-derived
neurons and show a positive correlation
between decreases in sAPPb and decreases
in pTAU.
(C) hiPSC neurons with the APP Swedish
(Swe) mutation introduced by genome edit-
ing show substantial increases in Ab pep-
tides in either heterozygous (Swe/wild-type
[WT]) or homozygous (Swe/Swe) genotypes
compared with the WT isogenic controls.
(D) Increased levels of Ab peptides do not
affect the observed decrease in the pTAU/
tTAU ratio mediated by R33 treatment.
(E) Compound E treatment substantially de-
creases Ab peptides in hiPSC-derived neurons
and treatment with R33 further decreases
Ab peptides in this condition, *** represents
statistical difference from vehicle; * repre-
sents statistical difference between com-
pound E alone and compound E + R33.
(F) Ab reduction does not change the fold-
decrease in the pTAU/tTAU ratio mediated
by R33.
(A and B) A linear regression analysis was
performed between Ab and pTAU (A) and
sAPPb and pTAU (B). R2 values reported on
graphs. (C) For each comparison, a one-way
ANOVA with a Tukey multiple comparisons
posttest was performed. (D and F) For each
comparison, a two-tailed t test was per-
formed. n = 3 independent experiments per
treatment/condition.
Error bars represent SD. *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001.in pTAU (Figure 5A). Previous work in hiPSC-derived neu-
rons has suggested that beta cleavage of APP, rather than
Ab, is more highly associated with TAU phosphorylation
(Israel et al., 2012), so we also examined the levels of
sAPPb compared with pTAU and observed a similar, but
less robust, correlation between the reduction in sAPPb
with pTAU (Figure 5B). Taken together, however, these
data suggest that the reduction in pTAU by R33 is highly
correlative with a reduction in amyloidogenic processing
of APP.1052 Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018We next asked if modulation of Ab levels affected the
decrease in pTAUby R33.Wemeasured pTAU from isogenic
neurons harboring the APP Swedishmutation, which leads
to a 2- to 3-fold increase in endogenous Ab in heterozygous
andhomozygous carriers, respectively (Figure 5C). Interest-
ingly, we did not observe increased levels of pTAU/tTAU ra-
tio in cells harboring these mutations alone. Previous work
using isogenic cell lines of another penetrant ADmutation,
PSEN1DE9, also failed to show increased pTAU/tTAU ratios
at baseline conditions (Woodruff et al., 2013). However,
treatment with R33 reduced the pTAU/tTAU ratio in the
isogenic neurons to the same extent across this allelic se-
ries, with no significant difference in R33-mediated TAU ra-
tio reduction between the wild-type cells and the Swedish
genotypes (Figure 5D), suggesting that retromer stabiliza-
tion reduces TAU phosphorylation regardless of genetic
condition. To test whether modulating level of the APP
b-CTF in our cell cultures affected the R33-mediated reduc-
tion of the TAU ratio, we treated wild-type purified neurons
with the gamma-secretase inhibitor compound E, which
inhibits the generation of Ab but increases the amount of
the b-CTF of APP. Interestingly, R33 treatment further
reduced the amount of Ab remaining after compound
E treatment (Figure 5E). The presence of compound E had
no effect on the decrease pTAU/tTAU ratio after treatment
with R33 (Figure 5F). Taken together, these data suggest
that while the pTAU/tTAU reduction by R33 is highly
correlative with Ab peptide levels, modulation of APP pro-
cessing, either up or down, does not change the R33-medi-
ated reduction of pTAU.
R33 Reduction of Phospho-TAU in hiPSC-Derived
Neurons Is Independent of APP Expression
Because hiPSCs are amenable to genome engineering, we
generated an APP knockout (APP KO) hiPSC line from our
parental APP duplication hiPSC line (APPDp1) using
CRISPR/Cas9 genome editing. APP KO hiPSCs were gener-
ated from FAD APPDp parental line by excision of one
copy ofAPP and the introduction of two premature stop co-
dons via non-homologous end-joining in the remaining
copies (R. Van der Kant et al., personal communication;
Figures S5A and S5B). APP KO hiPSCs have no detectable
APP protein by western blot analysis (Figure S5C). We
differentiated and purified neurons from APP KO hiPSCs
and confirmed that these neurons do not have detectable
levels of secreted Ab peptides by ELISA (Figure 6A). We
next treated APP KO neurons with R33 and observed
decreased pTAU from APP KO neurons (Figure 6B) with
no change in tTAU (Figure 6C), again leading to a signifi-
cant reduction in the pTAU/tTAU ratio in APP KO neurons
(Figure 6D). When APP KO neurons were transduced with
shVPS35-c, we documented a significant increase in the
amount of pTAU (Figure 6E), and this effect was confirmed
with a second shRNA, shVPS35-d (Figure S6A). Finally, we
tested whether VPS35 knockdown would change the effect
of R33 on pTAU levels in APP KO neurons. Interestingly,
knockdown of VPS35 did not affect the R33-mediated
reduction in pTAU in these cells (Figure S6B). However,
this result is not overly surprising, as we have an incom-
plete loss of VPS35 (50%) and the R33 chaperone is still
stabilizing the remaining retromer. Indeed, previous
work demonstrates that retromer stabilization chaperones
continued to stabilize two of the three cargo-recognitioncore proteins (VPS29 and VPS35) under single knock-
down conditions (shVPS26) (Mecozzi et al., 2014). Taken
together, these experiments suggest that retromer stability
influences TAU phosphorylation and that this is mediated
through an APP-independent mechanism. Furthermore,
these data imply that retromer enhancement may be bene-
ficial even under less than optimal retromer conditions,
such as loss of VPS35 expression, a condition documented
in AD patient tissue (Small et al., 2005).DISCUSSION
In this work, we demonstrate that a small molecule stabi-
lizer of the retromer complex reduces endogenous cellular
AD phenotypes in human neurons. This small molecule,
R33, has been previously shown to reduce Ab peptides
and decrease APP in early endosomes, consistent with its
in vitro action as a pharmacological chaperone that stabi-
lizes the retromer complex (Mecozzi et al., 2014) (Chu
and Pratico, 2017). We extended this work in human neu-
rons to test how retromer stabilization affects TAU phos-
phorylation, another critical pathologic phenotype in AD
and one that correlates more highly with cognitive decline
than the presence of amyloid plaques in patients (Arriagada
et al., 1992). In this work, we demonstrate that retromer
stabilization in human neurons reduces TAU phosphoryla-
tion at two epitopes, suggesting that this strategy may be
beneficial for pathologies extending beyond amyloid.
Indeed, while the focus on Ab as the premier pathological
event has undoubtedly yielded insights into the disease,
particularly for FAD, it is equally conceivable to envision
a ‘‘dual-pathway’’ hypothesis where an upstreammolecular
driver influences Ab and TAU pathologies separately (Small
and Duff, 2008). This may especially be the case for SAD,
where immense genetic heterogeneity and complex envi-
ronmental interactions have unknown influences on the
course of the disease. Here we decouple the effect of retro-
mer stabilization on both APP processing and TAU phos-
phorylation using gene-edited hiPSC-derived neurons. In
both neurons engineered to have 2- to 3-fold higher
amounts of Ab (APPSwe) or neurons engineered to not ex-
press APP and which have no detectable Ab (APP KO), ret-
romer stabilization decreases TAU phosphorylation to the
same extent, suggesting that manipulation of endocytic
trafficking via retromer may be an upstream driver of these
two pathologies independently from one another. This
approach of gene editing in pluripotent stem cells allows
the dissection of relevant disease biology in a human-spe-
cific system.
The link between retromer regulation of endosomal traf-
ficking and TAU phosphorylation is currently unclear,
although compelling studies are emerging to suggest thatStem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 1053
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Figure 6. Retromer Stabilization De-
creases the pTAU/tTAU Ratio and Knock-
down of Retromer Assembly Subunit
VPS35 Increases pTAU/tTAU Ratio Inde-
pendently of APP Expression in Human
Neurons
(A) APP KO neurons were generated from
APPDp cells by CRISPR/Cas9 genome editing
have no detectable levels of Ab peptides.
(B) APP KO neurons show a significant
reduction in pTAU (Thr 231) after treatment
with R33.
(C) tTAU levels are not affected in APP KO
neurons after treatment with R33.
(D) The pTAU/tTAU ratio is significantly
reduced in APP KO neurons after treatment
with R33.
(E) APP KO neurons transduced with VPS35
shRNA show a significant increase in pTAU/
tTAU ratio compared with scrambled shRNA
(SCR shRNA).
n = 3 independent experiments per treat-
ment/condition. For each comparison, a
two-tailed t test was performed. **p < 0.01,
***p < 0.001, ****p < 0.0001. NS, nonsig-
nificant. Error bars represent SD. See also
Figures S5 and S6.endocytic trafficking may directly affect TAU pathology.
Michel et al., 2014, suggest thatmonomeric TAU is endocy-
tosed from the extracellular space and its transit through
endosomes facilitates TAU seeding and aggregation. Work
in flies demonstrates that removing cathepsin D, a retro-
mer cargo and integral enzyme in lysosomal degradation,
exacerbates TAU-induced neurodegeneration (Khurana
et al., 2010). Extracellular TAU can be taken up and propa-
gated via exosomes inmicroglia, the resident immune cells
of the CNS (Asai et al., 2015), and retromer deficiency im-
pairs the recycling of TREM2 protein, a product of the
TREM2 gene that is also associated with increased AD
risk, which can inhibit microglial activation (Yin et al.,
2016). Developing methods of improving endocytic traf-
ficking and function in multiple CNS types will likely be
protective in many neurodegenerative disorders, under-
scoring the importance of elucidating the role of the endo-1054 Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018cytic network in both Ab and TAU pathology. Finally, we
highlight the potential of hiPSC models to confirm and
elaborate on work done in non-human systems. We have
replicated work previously published in mice to show
that retromer stabilization decreases pathogenic APP pro-
cessing (Mecozzi et al., 2014) and extended our studies to
show a beneficial effect of retromer stabilization on TAU
in human neurons, which, to our knowledge, has not
been documented previously. Furthermore, we demon-
strate that this process correlates with, but is not dependent
upon, APP processing.
Considering that the current failure rate of AD clinical tri-
als is very high (Posner et al., 2017), new therapeutic strate-
gies aimed at improving retromer and other endocytic
network component function are likely to be promising
therapeutic options. Indeed, recent genetic findings impli-
cate endosomal and vesicular trafficking genes in both
early- and late-onset AD (Bellenguez et al., 2017; Kunkle
et al., 2017; Rosenthal and Kamboh, 2014). For that reason,
and because defects in the endocytic pathway occur early
in AD pathogenesis, targeting this pathway represents a
valid cell biological target for therapeutic development
(Small et al., 2017).
The use of hiPSCs, which can be differentiated into all
cell types of the CNS, represents an ideal model to test
novel and existing drugs and other therapies in a preclini-
cal system. In particular, the advantage of a system that
does not rely on overexpression of disease proteins has
already been shown: patient-derived neurons behave
differently from APP-overexpressing cell lines and animal
AD model-derived neurons when exposed to drug candi-
dates, such as gamma-secretase modulators (Liu et al.,
2014). Recently, cortical neurons from hiPSCs have been
used to screen modulators of Ab peptide length (Brown-
john et al., 2017), and work in scalable three-dimensional
culture formats has shown detection of TAU aggregates in
a quantifiable manner in 384-well plates (Medda et al.,
2016), representing a growing technology involving
complex cellular interactions that will likely be highly
translational.
Abnormalities in the endo/lysosomal network are a
common theme in multiple neurodegenerative disorders
(Hu et al., 2015; Schreij et al., 2016), and retromer-related
mutations or defects are implicated not only in AD, but Par-
kinson disease and Down syndrome, as well as other non-
neurological conditions (Berman et al., 2015). Our work,
for the first time, examines a small molecule that en-
hances the function of retromer, which is an integral
component of the endosomal network, using human neu-
rons. This pharmacologic chaperone, R33, demonstrated
pronounced and potentially beneficial effects on the two
main pathological molecules in AD: Ab and pTAU. We pre-
dict that using hiPSCs, both from patients and isogenic
lines with key mutations or variants, to test and screen
novel therapeutic molecules and other therapeutic
strategies will represent a major advance in therapeutic
development for AD and other complex neurodegenerative
disorders.EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
All patient-derived hiPSC lines were generated by four-factor re-
programming and have been previously characterized and pub-
lished (Israel et al., 2012; Young et al., 2015). Briefly, hiPSCs were
maintained on a mouse embryonic fibroblast (MEF) feeder layer
in HUES medium and were routinely tested for mycoplasma.
NSCs and neurons were generated using previously described
methods (Israel et al., 2012; Yuan et al., 2011) and purified by fluo-
rescence-activated cell sorting (FACS). After FACS purification, de-pending on the percentage of neurons in each differentiation, 2 to
4 independent purified cultures were re-plated for each experi-
ment. From these independent cultures and for each assay, 2 to
4 technical replicates from each well were analyzed.
CRISPR/Cas9 Gene Editing
Genome-edited lines were generated using published protocols.
Briefly, guide RNAs (gRNAs) to APP were generated using the
Zhang Lab Crispr design Web site at MIT (crispr.mit.edu) and
cloned into vector px458 (Addgene) that co-expresses the Cas9
nuclease and GFP. hiPSCs were electroporated with the px458
plasmid containing the gRNAs to target APP. We generated the
APP KO cells from our parental APPDp cell line (APPDp1), first
described in Israel et al., 2012. To generate APP KO cells, no repair
template was added. For generating the APP Swedish mutation,
we targeted wild-type hiPSCs derived from J. Craig Venter (Gore
et al., 2011) and 120-bp single-stranded oligonucleotide was de-
signed to have the 2-bp Swedishmutation (GA to TC, correspond-
ing to exon 16 of APP). Electroporated hiPSCs were sorted for GFP
and plated a clonal density on 10-cm MEF plates. After 1.5 to
2.0 weeks, sub-cloned colonies were picked and transferred to a
96-well plate. Colonies were spit in duplicate and one set was
maintained for cell line generation and the other was analyzed
for the mutation of interest by Sanger Sequencing. All gene-edi-
ted lines were digitally karyotyped as euploid by the Illumina In-
finium HumanCoreExomeBeadChip, as has been previously
described (Young et al., 2015)
Drug Treatment and ELISA Assays
Pure R55 and R33 were obtained from MedKoo Biosciences (prod-
ucts TPT-260 and TPT-172) and re-suspended at designated con-
centrations in a solution of 50% DMSO/50% double-distilled
H2O at low pH (pH 4.3). For these studies, R33 was used for every
experiment. Purified neurons were treated with R33 or vehicle
(DMSO/H2O) for 72 hr and then harvested for analysis. For
Ab and TAU ELISA assays, purified neurons were seeded at
200,000 cells/well of a 96-well plate. After treatment, cell culture
media and cell lysate were harvested from triplicate wells and
run onAbTriplex ELISA plates and pTAUThr231/tTAUELISA plates
(Meso Scale Discovery). Protein concentrations were determined
by BCA assay (Pierce) and Ab levels were normalized to the amount
of total protein.
Western Blotting
Cell lysates were run on NuPAGE 4% to 12% Bis-Tris Gels, trans-
ferred to nitrocellulose membranes, and probed with antibodies
to VPS35 (Abcam #ab57632), APP (Life Tech #512700), TAU
(Thermo #MN1000 and MN#1020). Quantification of western
blots was performed on the Odyssey system and using ImageJ
software.
shRNA Design and Virus
shRNAs against VPS35 were ordered from Origene (#TL300553).
VPS35 and scrambled control shRNAs were packed into lentivirus
using HEK293FT cells. Virus was purified by PEG-it and cells were
transduced with lentivirus for 72 hr. Knockdown of VPS35 was
confirmed by qRT-PCR and western blot analysis.Stem Cell Reports j Vol. 10 j 1046–1058 j March 13, 2018 1055
gRNA, ssODN, and Primer Sequences
gRNA to generate APP Swedish and APP KO cells: GGAGATCTCT
GAAGTGAAGA TGG.
ssODN for APP Swedish homologous recombination 2-bp
change in bold: TGATGTAATACAGGTTCTGGGTTGACAAATATC
AAGACGGAGGAGATCTCTGAAGTGAATCTGGATGCAGAATTCC
GACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTACGT.
VPS35 primer for qRT-PCR: F primer, TGCCCACCAGACTAT
CAGTG; R primer, AGCTGCACTTGTAGAGAGGG.Statistical Methods
Statistics for all datasets were performed using GraphPad Prism.
Normality for each dataset was assessed using the D’Agostino-Pear-
son test. When data were normally distributed, a parametric two-
tailed t test was used. The comparisons betweenmultiple cells lines
from different individuals usually resulted in non-normally
distributed data and these data were analyzed using the Wil-
coxon-signed rank test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found
with this article online at https://doi.org/10.1016/j.stemcr.2018.
01.031.
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